Jardiance

Product manufactured by Remedyrepack Inc.

Application Nr Approved Date Route Status External Links
NDA204629 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Jardiance Is Indicated: As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus, To Reduce The Risk Of Cardiovascular Death In Adult Patients With Type 2 Diabetes Mellitus And Established Cardiovascular Disease. Limitations Of Use Jardiance Is Not Recommended For Patients With Type 1 Diabetes Or For The Treatment Of Diabetic Ketoacidosis. Jardiance Is A Sodium-Glucose Co-Transporter 2 (sglt2) Inhibitor Indicated: As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus, To Reduce The Risk Of Cardiovascular Death In Adult Patients With Type 2 Diabetes Mellitus And Established Cardiovascular Disease. ( 1 ) Limitations Of Use: Not For The Treatment Of Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Empagliflozin EMPAGLIFLOZIN ZINC36520252

Comments